HRTX Heron Therapeutics, Inc.

15.70
+0  (2%)
Previous Close 15.40
Open 15.45
Price To book 0.00
Market Cap N/A
Shares 0
Volume 336,362
Short Ratio 0.00
Av. Daily Volume 787,334

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17757049
  2. 8-K - Current report 17733114
  3. 8-K - Current report 17698171
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17633084
  5. 8-K - Current report 17632979

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Phase 3 trial to be initiated in 2017.
HTX-011
Hernia repair
Phase 2 data released August 2016
HTX-011
Bunionectomy
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
NDA filing announced January 12, 2017.
HTX-019
Prevention of chemotherapy-induced nausea and vomiting (CINV)

Latest News

  1. Overcoming Opioids: The quest for less addictive drugs
  2. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : April 5, 2017
  3. Heron Therapeutics to Present at the 16th Annual Needham Healthcare Conference
  4. Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  5. Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : March 9, 2017
  6. Heron Therapeutics Inc (HRTX) Sustol To Be Included In Antiemesis Guidelines By NCCN
  7. Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference
  8. Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines
  9. Heron Therapeutics reports 4Q loss
  10. Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress
  11. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  12. Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  13. LifeSci Capital Initiates Coverage of Heron Therapeutics
  14. Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares
  15. Legendary Railroad Executive Offloads Huge Amount of Shares After Announcing Decision to Retire from Canadian Pacific Railway, Plus Other Insider Trading
  16. Heron Therapeutics Launches $150M Public Offering
  17. Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
  18. Heron Therapeutics Announces Proposed Public Offering of Common Stock
  19. Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
  20. Heron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference